Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06353997 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
A Phase 2 study of Triple Negative Breast Cancer, sponsored by Providence Health & Services.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 4
- Study locations
NCT06353997 is a Phase 2 study of Triple Negative Breast Cancer that is actively recruiting participants, run by Providence Health & Services. The registered enrollment target is 12 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06353997, a Phase 2 study of Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Providence Health & Services.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase II trial to assess efficacy and feasibility of pembrolizumab + INBRX-106 as an induction therapy preceding neoadjuvant therapy.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG INBRX-106
Study Locations (4)
Oregon
- Providence Portland Cancer Institute - Franz Clinic - Portland
- Providence St. Vincent Medical Center - Portland
California
- Ellison Institute of Technology (EITM) - Los Angeles
Washington
- Swedish Cancer Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-09-05 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06353997
The ClinicalTrials.gov registry entry for NCT06353997 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06353997 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Oregon, California, Washington.
Frequently Asked Questions
What is clinical trial NCT06353997 about?
NCT06353997 is a clinical study titled "Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients". This is a Phase II trial to assess efficacy and feasibility of pembrolizumab + INBRX-106 as an induction therapy preceding neoadjuvant therapy.
What is the current status of trial NCT06353997?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2024-09-05. Estimated completion is 2029-06.
What conditions does trial NCT06353997 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer.
What interventions are being tested in trial NCT06353997?
The interventions under investigation include: Pembrolizumab (DRUG), INBRX-106 (DRUG).
Who is sponsoring clinical trial NCT06353997?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06353997 being conducted?
This trial has 4 study locations across California, Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients
RECRUITING · Phase 2
-
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.